Impairment of the activin A autocrine loop by lopinavir reduces self-renewal of distinct human adipose progenitors

Sci Rep. 2017 Jun 7;7(1):2986. doi: 10.1038/s41598-017-02807-9.

Abstract

Maintenance of the adipose tissue requires a proper balance between self-renewal and differentiation of adipose progenitors (AP). Any deregulation leads either to fat overexpansion and obesity or fat loss and consequent lipodystrophies. Depending on the fat pad location, APs and adipocytes are heterogeneous. However, information on the pharmacological sensitivity of distinct APs to drugs known to alter the function of adipose tissue, especially HIV protease inhibitors (PIs) is scant. Here we show that PIs decreased proliferation and clonal expansion of APs, modifying their self-renewal potential. Lopinavir was the most potent PI tested. Decrease in self-renewal was accompanied by a reduced expression of the immediate early response gene IER3, a gene associated with tissue expansion. It was more pronounced in chin-derived APs than in knee-derived APs. Furthermore, lopinavir lowered the activin A-induced ERK1/2 phosphorylation. Expressions of the transcription factor EGR1 and its targets, including INHBA were subsequently altered. Therefore, activin A secretion was reduced leading to a dramatic impairment of APs self-renewal sustained by the activin A autocrine loop. All together, these observations highlight the activin A autocrine loop as a crucial effector to maintain APs self-renewal. Targeting this pathway by HIV-PIs may participate in the induction of unwanted side effects.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Activins / antagonists & inhibitors*
  • Adipose Tissue / cytology*
  • Cell Proliferation / drug effects*
  • Cells, Cultured
  • Gene Expression Regulation / drug effects
  • HIV Protease Inhibitors / adverse effects*
  • Humans
  • Lopinavir / adverse effects*
  • Protein Interaction Maps / drug effects
  • Stem Cells / drug effects
  • Stem Cells / physiology*

Substances

  • HIV Protease Inhibitors
  • activin A
  • Activins
  • Lopinavir